The latest filing does not contain sufficient reviewed comparable structured data
Last SEC check
Sep 13, 2026
Data basis
Official SEC · no quote feed
Component status
Filing EvidenceResearch CurrentOfficial SEC filing history is available
Structured FinancialsSource LimitedThe latest filing model has no reviewed comparable financial mapping · NO_CURRENT_COMPARABLE_STATE
Filing AnalysisSource LimitedNo filing analysis job is currently running · NO_CURRENT_COMPARABLE_STATE
Fundamental StateSource LimitedFundamental State depends on validated comparable financial metrics · NO_CURRENT_COMPARABLE_STATE
RESEARCH SNAPSHOTORAMED PHARMACEUTICALS INC.'s latest supported as-filed period reports revenue of $2.0M. Every value below links to its SEC accession and metric lineage.
INSIDER STATE / 90DRecent disclosed activity
Open-market purchases
0
Sales
0
Distinct buyers
0
Repeat buyer
NO
Conservative Form 4 classification · not a sentiment label
Flagship analysis / V3
What changed?
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Current 10-Q0001213900-26-0873613 governed changes · top 3 shown
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
As-filed financials
Financial trajectory
Each point keeps the date investors could first observe it and its accession.
As filedCurrent normalized · later
ACTIVE TRACE
Revenue
ORMP · as filed with the SEC · reported-date aware
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.